INS and type 2 diabetes mellitus: In their type-2 diabetes cohort study, Gamble et al. reported that patients treated with DPP-4 inhibitors showed no increase in fragility fracture risk compared to those receiving SU and insulin, and that they also showed reduced risk in comparison to those receiving thiazolidinediones [150].